Posts Tagged ‘clinical translation’

Improving ultrasound imaging may have applications in regenerative medicine

Author: Guest, 03/13/17

Andy Bell, a writer working with Toronto3dprinting, loves to write about different topics related to technological gadgets and gears. 3D printing is his current interest. Though ultrasound technology is commonly associated with the imaging of fetuses in the womb, its applications are much more than just imaging. The acoustic waves generated by ultrasound devices can…Read more

A new style of MSC immunotherapy – Instructions included

Author: Holly Wobma, 09/22/16

If you have been following stem cell news lately, you know that there have been several recent Food and Drug Administration (FDA) meetings regarding how to classify stem cells, which ultimately affects if and how they will be regulated. There are many medical practitioners, scientists, and patients who would like to see these therapies on…Read more

Right Turn: Animals, ethics and Orwell

Author: Stacey Johnson, 07/08/16

Much has been said on the topic of using animals for medical/scientific research. There are excellent and compelling arguments for and against the issue and my plan is to avoid taking a stand here. (You may be tempted to call me chicken, but that would be a really bad pun!) As polarizing as this topic…Read more

Immunotoxins: a surprisingly less toxic approach to stem cell transplants

Author: Holly Wobma, 07/06/16

It is often the case that to produce something ‘shiny,’ new and better, we must first get rid of the old. This is true even in the case of stem cell therapies. Hematopoietic stem cell (HSC) transplants have been around since the mid-twentieth century and are used to treat a broad range of diseases such…Read more

Highlights from the World Biomaterials Congress Part II: Stepping up delivery strategies

Author: Samantha Payne, 06/20/16

This post is the second of two covering the World Biomaterials Congress. To read my previous blog about the use of biomaterials to study cell behaviour and differentiation in vitro, please click here. This post will cover the use of biomaterials for in vivo delivery strategies. Cartilage, despite its essential role in the movement of…Read more

Update from the Clinic: March

Author: Mark Curtis, 04/28/16

Welcome to your Update from the Clinic for the month of March. Undoubtedly the big news in March came from Vericel, which saw its stock double after reporting positive topline results from its Phase 2b study in heart failure. There were also some first dosings and clinical study starts. A study of Vericel’s (VCEL) ixmyelocel-T…Read more

Cell Therapy Deal Review: March

Author: Mark Curtis, 04/25/16

Welcome to your Cell Therapy Deal Review for the month of March. Cellectis continues to differentiate through a collaboration with MabQuest. PCT formed a partnership with Japanese conglomerate Hitachi. Kite partnered with Roche’s Genentech on a program for lymphoma. Cellectis (CLLS) has already separated itself from the pack with UCART19, a universal CAR product targeting…Read more

Cell Therapy Deal Review: February

Author: Mark Curtis, 03/15/16

Welcome to your deal review for the month of February. Astellas tied-off its acquisition of Ocata while GSK and Adaptimmune expanded their collaboration to develop cell-based immunotherapies. AVROBIO, a new cell and gene company based in Boston, Mass, and Toronto, Ontario, launched with programs in leukemia in Fabry disease. After a drawn out process, Astellas…Read more

Right Turn: Bio-hybrid device mimics kidney to remove need for dialysis

Author: Stacey Johnson, 03/04/16

Last week, I wrote about Dr. Leon Bellan’s creative solution to engineering artificial blood vessels for lab-grown organs: cotton candy! As much as I was impressed with his out-of-the-box thinking, I also really liked the excellent video produced by Vanderbilt University (VU), where Dr. Bellan runs his lab. So I went hunting for other VU…Read more

Cell Therapy Deal Review: January

Author: Mark Curtis, 02/18/16

Welcome to your Cell Therapy Deal Review for the month of January. Things got off to a quick start with a number of cell-based immunotherapy companies announcing deals and research collaborations out of the gate, including a third acquisition by Juno. Juno Therapeutics (JUNO) brought further depth to its research & discovery platform through the…Read more